How is this NOT on every screen like the first batch of Fauci e-mails?!?!

(Washington, DC) Judicial Watch announced on 4th of June 2021 that it obtained 280 pages of documents from the Department of Health and Human Services revealing that from 2014 to 2019, $826,277 was given to the Wuhan Institute of Virology for bat coronavirus research by the National Institute of Allergy and Infectious Diseases (NIAID), which is headed by Dr. Anthony Fauci. 

The documents, some of which were redacted or withheld in their entirely, were obtained through a Freedom of Information Act (FOIA) lawsuit seeking records of communications, contracts and agreements with the Wuhan Institute of Virology in China (Judicial Watch, Inc. v. U.S. Department of Health and Human Services (No. 1:21-cv-00696)). The agency is only processing 300 pages records per month, which means it will take until the end of November for the records to be fully reviewed and released under FOIA.

The records include a chart of NIAID funding to the Wuhan Institute of Virology sent on April 21, 2020, by NIAID’s Chase Crawford to Principal Deputy Director Hugh Auchincloss and other NIAID officials. The agency funds directed to the Wuhan Institute of Virology between the years 2014-2019 total $826,277. All of the projects listed in the chart are titled “Understanding the Risk of Bat Coronavirus Emergence.”

In an April 15, 2020 email marked “high” importance, Principal Deputy Director of NIH Lawrence Tabak emailed Fauci, NIH Director Francis Collins, and other NIH officials with the subject line: “HEADS UP: Wuhan lab research:”

Tabak: WH has strongly embraced concerns raised by Congressman Gaetz who is publicly criticizing HHS/NIH for funding the Wuhan laboratory’s bat research. Here’s this quote from another article: “I’m disgusted to learn that for years the US government has been funding dangerous and cruel animal experiments at the Wuhan Institute, which may have contributed to the global spread of coronavirus, and research at other labs in China that have virtually no oversight from US authorities.” [Emphasis in original]

This is a large multi-country study with Wuhan being one site. The principal investigator, Peter Daszak, is based in NY at EcoHealth Alliance, Inc. [Emphasis in original]

Tabak provides details of the grant to Peter Daszak, president of EcoHealth Alliance, for a project titled “Understanding the Risk of Bat Coronavirus Emergence.” Tabak continues, saying, “The 3.7M dollar figure is over 6 years to all sites which include (several in) China, Thailand, Cambodia, Laos, Vietnam, Malaysia, Indonesia and Myanmar. We estimate that approximately $826,300 has been spent at this site since the inception of the grant. Yearly costs appear to be about 80K/year. The grant is in year 6 of a total of 10 year.”

Also read: US RAN GRUESOME BIOWEAPON RESEARCH IN OVER 25 COUNTRIES. WUHAN, TIP OF AN ICEBERG. ECOHEALTH ALLIANCE IMPLICATED AGAIN

A January 9, 2020, email exchange labeled “high” importance between NIAID Senior Scientific Advisor Dr. David Morens and Daszak details the relationship between the Fauci agency and the Wuhan Institute of Virology: 

Morens: Hi guys, do any of you have any inside info on this new coronavirus that isn’t yet in the public domain? Or any thoughts? 

Daszak: Yes – lots of information and I spoke with Erik Stemmy and Alan Embry yesterday before the news was released. Erik is my program officer on our coronavirus grant specifically focused on China…. 

Morens: Thanks, the excitement never ends, right?

Daszak: NIAID has been funding coronavirus work in China for the past 5 years … (1R01Al110964: “Understanding the Risk of Bat Coronavirus Emergence” ). That’s now been renewed … Collaborators include Wuhan Institute of Virology (currently working on the nCoV), and Ralph Baric [of University of North Carolina]. 

*** 

Also-FYI, prior to the R01, we worked under an R01 with Eun-Chung Park as program officer on viral discovery in bats, where originally identified SARS-CoV as having a likely origin in bats (published in Science)….

Morens: Great info, thanks. Tony doesn’t maintain awareness of these things and doesn’t know unless program officers tell him, which they rarely do, since they are across town and may not see him more than once a year, or less…. Interested in your feeling about where this is going. The experts are buzzing around us are all over the map, between doomsday and not that big a deal, with everything in between.

On January 23, 2020, a senior NIH official Melinda Hoskins forwarded a Daily Mail article to colleagues discussing NIH/NIAID funding of the bat virus research, and noting that Fauci would be briefing senators the following morning. Hoskins says, “Would you please confirm the exact nature of our support to the Wuhan Institute of Virology/Biosafety Lab.” 

Another official, Barbara Mulach, responds that, “We’ve identified one grant with a sub-grant to Wuhan Institute of Virology (thanks for the lead) and one primary grant to Wuhan University. We are trying to get clarification whether or not the two organizations are related so we know if the second application is relevant to the request or not.”

She provides data showing a “Sub-award to Wuhan Institute of Virology,” with Daszak as principal investigator for a project titled, “Understanding the Risk of Bat Coronavirus Emergence,” and she provides information on another award, grant number R01AI119064-06, with principal investigator Ke Lan, going to Wuhan University and titled, “Versatile functions of LANA in KSHV pathogenesis.”

In an April 13, 2020, email from NIH official Emily Erbelding to NIH colleagues, Erbelding notes that the “entire amount of the new Daszak grant (year 6 funded in FY19) is about 3.64 M. The total amount that will go to Wuhan Institute of Virology under this grant will be about $750K ($76,301 had already been sent to Wuhan in year 1 according to the NOA).” Additionally, the email notes that bat sampling work done during years 2011-2015, in addition to receiving funding from Daszak’s grant, “could also have been supported by USAID Predict program (which was also funding the Wuhan lab).”

Also read: TRIPLE-BOMBSHELL ON #WUHAN: #FAUCI, #WHO AND #CCP INVOLVED IN GAIN-OF-FUNCTION RESEARCH JUST PRIOR TO “PANDEMIC”

Auchinloss forwards Erberlding’s note to Fauci, saying, “This is higher but not extraordinarily higher than I originally indicated which was for some earlier work.” Fauci replies, “Thanks.”

In an April 15, 2020, email exchange, Tabak asks his colleagues if Daszak’s team had “published anything seminal related to the current pandemic.” Erbelding responds, “Peter’s only publication on SARS CoV2 since the epidemic began is thought piece in NEJM [New England Journal of Medicine]” to which she provides a hyperlink. She adds, “Note that all of the prior work on zoonotic reservoirs of CoV’s was also supported by USAID funding through a program called PREDICT, which has since ended.”

On October 1, 2017, after receiving Daszak’s email related to his then-unpublished paper describing detailed research into a novel bat-born virus tied to Swine Acute Diarrheal Syndrome, Fauci forwards Daszak’s email and paper on to NIH official Greg Folkers, saying, “Confidential, but fyi for you.” Daszak says, “You should know that this work was supported by a NIAID ROl that [NIH’s] Erik Stemmy is the Program Officer for, and that I’m PI [principal investigator] on, with Zhengli Shi [the director of the Center for Emerging Infectious Diseases of the Wuhan Institute of Virology] as co-PI.”

Also read: LMFAO! FAUCI’S WUHAN MIDDLEMAN, PETER DAZSAK CO-AUTHORED A STUDY WITH “ANTI-VAXX GURU” ANDREW WAKEFIELD

A person whose name is redacted on April 19, 2018, CCs an email to “International Cables (HHS/OS)” with the subject line “China Virus Institute Welcomes More U.S. Cooperation on Global Health Security,” includes a U.S. cable: 

China’s Wuhan Institute of Virology, a global leader in virus research, is a key partner for the United States in protecting global health security. Its role as operator of the just-launched Biosafety Level 4 (or ‘P4’) lab- the first such lab in China – opens up even more opportunities for expert exchange, especially in light of the lab’s shortage of trained staff.

***

In the last year, the lab also hosted visits from the National Institutes of Health, National Science Foundation, and experts from the University of Texas Medical Branch in Galveston. The institute reports to the Chinese Academy of Sciences in Beijing.

P4 Lab is Open and Transparent, Officials Emphasize

 ***

Officials described the lab as a “regional node” in the global biosafety system and said it would play an emergency response role in an epidemic or pandemic. The lab’s English brochure highlighted a national security role, saying that it is “an effective measure to improve China’s availability in safeguarding national bio-safety if [a] possible biological warfare or terrorist attack happens.”

Institute officials said there would be “limited availability” for international and domestic scientists who had gone through the necessary approval process to do research at the lab. They stressed that the lab aimed to be a “worldwide, open platform” for virology. They said they welcomed U.S. Centers for Disease Control (CDC) experts, noting that the Chinese Academy of Sciences was not strong on human disease expertise, having only focused on it in the last 15 years, after the SARS outbreak. A Wuhan-based French consulate official who works on science and technology cooperation with China also emphasized that the lab, which was initiated in 2004 as a France-China joint project, was meant to be “open and transparent” to the global scientific community. “The intent was to set up a lab to international standards, and open to international research,” he said. French experts have provided guidance and biosafety training to the lab, which will continue, the French official said. Institute officials said that France provided the lab’s design and much of its technology, but that it is entirely China-funded and has been completely China-run since a “handover” ceremony in 2016. 

In addition to French assistance, experts from the NIH-supported P4 lab at the University of Texas Medical Branch in Galveston have trained Wuhan lab technicians in lab management and maintenance, institute officials said.… One Wuhan Institute of Virology researcher trained for two years at the Galveston lab, and the institute also sent one scientist to U.S. CDC headquarters in Atlanta for six months’ work on influenza.

            NIH-Supported Research Revises SARS Origin Story

NIH was a major funder, along with the National Science Foundation of China (NSFC), of SARS research by the Wuhan Institute of Virology’s [redacted.]

*** 

Ready to Help with the Global Virome Project

Institute officials expressed strong interest in the Global Virorne Project (GVP), and said Chinese funding for the project would likely come from Chinese Academy of Sciences funding already earmarked for One Belt, One Road-related initiatives…. GVP aims to launch this year as an international collaborative effort to identify within ten years virtually all of the planet’s viruses that have pandemic or epidemic potential and the ability to jump to humans. “We hope China will be one of the leading countries to initiate the Global Virome Project,” one Wuhan Institute of Virology official said. China attended a GVP unveiling meeting in January in Thailand and is waiting for more details of the initiative. The officials said that the Chinese government funds projects similar to GVP to investigate the background of viruses and bacteria. This essentially constituted China’s own Virome Project …

Also Read: INDIA BLACKLISTED US CDC FOR SECRETLY FUNDING BIOWEAPONS RESEARCH IN MANIPAL

U.S.-China Workshop Explores Research Partnerships

***

 Some workshop participants also expressed skepticism about the Global Virome Project’s (GVP) approach, saying that gaining a predictive understanding of viruses with pandemic potential would require going beyond the GVPs strategy of sample collection, to take an “ecological” approach that considers the virome beyond vertebrate systems to identify mechanisms driving pathogen evolution. A follow-on workshop will be held in June at the University of Berkeley. NSF and NSFC hope to jointly announce a funding call for collaborative projects later this year.

On April 14, 2020, NIH official Marshall Bloom forwarded a Washington Post article by Josh Rogin titled “State Department Cables Warned of Safety Issues at Wuhan Lab Studying Bat Coronaviruses,” and asked a colleague to “Please send to the HCTF [High Containment Task Force]. Thanks!”  

After receiving an article via an email on November 1, 2013, from NIH official Greg Folkers with a cartoon depicting a bat depositing coronavirus particles attacking human ACE2 receptor cells, his colleague, Fauci’s Special Assistant Patricia Conrad writes, “I think we need more slides like this…its too cute!”

A January 19, 2018, State Department cable from the US Embassy in Beijing about the Wuhan Institute of Virology with the subject “China Opens First Bio Safety Level 4 Laboratory” includes a section titled “Unclear Guidelines on Virus Access and a Lack of Trained Talent Impede Research,” which notes in its introduction that “its current productivity is limited by a shortage of highly trained technicians and investigators required to safely operate a BSL-4 laboratory and a lack of clarity in related Chinese government policies and guidelines.”

The memo continues: “To date, WIV [Wuhan Institute of Virology] has obtained permission for research on three viruses: Ebola virus, Nipah virus, and Xinjiang hemorrhagic fever virus (a strain of Crimean Congo hemorrhagic fever found in China’s Xinjiang Province.)”

“These new documents show that funding for the Wuhan Institute was greater than the public has been told,” said Judicial Watch President Tom Fitton. “That it has taken a year and a federal lawsuit to get this first disclosure on COVID and Wuhan is evidence of cover-up by Fauci’s agency.”

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

If you’re a regular follower of ours or Dr. Lee Merrit’s, some of the info in the video below is not latest minute news. I wanted to save this presentation on the website though, for two main reasons: it brings a few new angles, such as the racial one, and it’s really well structured and rounded, managing to paint a complex picture in under 15 minutes. There may be a lot left to say, but this makes the case and it can stand alone. Reference material, at least until science proves otherwise, which seems highly unlikely to me, so far.

“Merritt has an impressive resume as an orthopedic surgeon and military doctor. However, she is also the former president of the conservative medical advocacy group the Association of American Physicians and Surgeons (AAPS), which opposes vaccines, the Affordable Care Act and all government healthcare, including Medicare…

Dr. Merritt has certainly accomplished a great deal as a surgeon, including being the first woman to receive the Louis A. Goldstein Spine Surgery Fellowship at the Rochester Strong Memorial Hospital in New York.”  – The Millenial Source

This profile has been written by her detractors.

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

Not the writer, the first man to undertake the Covid gene therapy.

I closed the case in this post’s cover gif animation.
All I have to add is a few references:

SOURCE
Source
SOURCE
SOURCE


“Experimental” means we are not done finding out what relates to it, how and when.

SILVIEW.media

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

This is just one expert testimony in the Texas Senate hearings on vaccine mandates, May 16 2021. But it lines up with many other testimonies and reports and with the explosive situation revealed by VAERS and other official stats, so it’s hard to believe that only happens in Texas. And if it does, rest assured this is going to be the norm soon, whether officially reported or not. You don’t need medical knowledge anymore to tell that, we have enough data to be able to anticipate the trends using basic math now, as I’ve shown before and I’ve only been proven right since.

CLICK HERE TO WATCH ALMOST ONE HOUR OF DAMNING EXPERT TESTIMONIES FROM THE SAME HEARING!

Also see: HOW MANY THOUSANDS VAERS REPORTS IS CDC SITTING ON TO SELL MORE VACCINES?!

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

I’m trying to advance the discussion, but apparently most are still stuck at “these are not even vaccines”. Yeah, we knew that the moment we visited a manufacturer’s website, which is among the first reasonable things to do. I hope this will help closing that debate and will ease stepping further down the rabbit hole. Watch how many will find out these things from me rather than from the original source!

mRNA doesn’t alter DNA?

mRNA is just as critical as DNA.

source: Moderna

Without mRNA, your genetic code would never get used by your body. Proteins would never get made. And your body wouldn’t – actually couldn’t – perform its functions. Messenger ribonucleuc acid, or mRNA for short, plays a vital role in human biology, specifically in a process known as protein synthesis. mRNA is a single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to ribosomes, the cell’s protein-making machinery.

Moderna

Our Operating System

Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the “program” or “app” is our mRNA drug – the unique mRNA sequence that codes for a protein.

We have a dedicated team of several hundred scientists and engineers solely focused on advancing Moderna’s platform technology. They are organized around key disciplines and work in an integrated fashion to advance knowledge surrounding mRNA science and solve for challenges that are unique to mRNA drug development. Some of these disciplines include mRNA biology, chemistry, formulation & delivery, bioinformatics and protein engineering.

Our mRNA Medicines – The ‘Software of Life’

When we have a concept for a new mRNA medicine and begin research, fundamental components are already in place.

Generally, the only thing that changes from one potential mRNA medicine to another is the coding region – the actual genetic code that instructs ribosomes to make protein. Utilizing these instruction sets gives our investigational mRNA medicines a software-like quality. We also have the ability to combine different mRNA sequences encoding for different proteins in a single mRNA investigational medicine.

We are leveraging the flexibility afforded by our platform and the fundamental role mRNA plays in protein synthesis to pursue mRNA medicines for a broad spectrum of diseases.

Within a given modality, the base components are generally identical across development candidates – formulation, 5’ region and 3’ region. Only the coding region varies based on the protein/s the potential medicine is directing cells to produce.

Learn how our Research Engine and Early Development Engine are enabling us to fully maximize the promise of mRNA to meaningfully improve how medicines are discovered, developed and manufactured.

‘Life is just a flow of information. And we’re interfering with it”

Overcoming Key Challenges

Using mRNA to create medicines is a complex undertaking and requires overcoming novel scientific and technical challenges. We need to get the mRNA into the targeted tissue and cells while evading the immune system. If the immune system is triggered, the resultant response may limit protein production and, thus, limit the therapeutic benefit of mRNA medicines. We also need ribosomes to think the mRNA was produced naturally, so they can accurately read the instructions to produce the right protein. And we need to ensure the cells express enough of the protein to have the desired therapeutic effect. 

Our multidisciplinary platform teams work together closely to address these scientific and technical challenges. This intensive cross-functional collaboration has enabled us to advance key aspects of our platform and make significant strides to deliver mRNA medicines for patients.

MODERNA

SOFTWARE OF LIFE™ Research and Design Services

Our mRNA RESEARCH ENGINE™ services enable us to advance new product ideas into development candidates via our drug discovery efforts, and includes infrastructure to enable rapid supply of thousands of preclinical mRNAs for research involving in vitro and in vivo experiments in order to accelerate programs from idea to development candidate designation.

 

mRNA Design Studio™ – Digital Design and Ordering of mRNA for Research

Our mRNA Design Studio enables rapid design of multiple mRNAs.

As our scientists create new mRNA concepts, they can design mRNAs for research and testing, within days, using our proprietary systems. As the Digital Biotech Company™, we utilize the software-like property of mRNA in our proprietary, web-based mRNA Design Studio. Our scientists request mRNAs for a specific protein, and the protein target is automatically converted to an initial optimized mRNA sequence. Using our Sequence Designer module, they can tailor entire mRNAs from the 5’-UTR to the coding region to the 3’-UTR based on our ever-improving proprietary learnings. The mRNA sequence is then further optimized using our proprietary bioinformatics algorithms. Our digital ordering then ensures rapid and accurate transmission of sequences to our modular synthesis robotics.

Our proprietary in-house digital application suite contains a Sequence Designer module to tailor an entire mRNA, with ever-improving rule sets that contain our accumulated learning about mRNA design. Drug Design Studio utilizes cloud-based computational capacity to run various algorithms we have developed to design each mRNA sequence. The utility of cloud-based capacity allows us to provide flexible computational capacity on demand, allowing the Research Engine to power parallel intake and design of multiple mRNA sequences.

Moderna’s Research Engine

Our Research Engine combines proprietary digital drug design tools and a highly automated production facility to enable Moderna and our strategic collaborators to move mRNA medicines swiftly through the research stage, from idea to development candidate nomination.

Scientists can begin by selecting any protein in the human proteome to be further engineered, including antibodies, or they can design novel proteins like traps, fusion proteins, or completely novel scaffolds and sequences. All can be designed to explore previously undruggable pathways.

The Drug Design Studio integrates with Moderna’s automation platforms – directing orders through each phase of mRNA synthesis. Once the order is placed, Moderna’s high-throughput mRNA pre-clinical production facility manages the manufacturing of mRNA constructs and delivers them in just weeks.

MODERNA

Is Humanity even trying to survive?!

PS: Some people wonder why the vids above are available on their website but unlisted on their Youtube.
It’s because they know you won’t look for them on their site, mostly potential partners will.

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We gave up on our profit shares from masks, if you want to help us, please use the donation button!
We think frequent use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness.
Get it here!

If you’re familiar with our reports, George Church is no stranger to you either. He’s a founder figure for the Human Genome Project, CRISPR and The BRAIN Initiative. But he’s totally not getting the deserved attention, seeing that he’s just turned our world upside down. Not by himself, of course.

Remember when Fauci and Big Tech joined efforts to keep us in the dark in regards to the mRNA impact on our genetics and DNA?


We’ve shown that there’s an entire new field of science that does just that: argues what Fauci said using RNA to reprogram DNA.
But we’ve just reached a deeper level of the rabbit hole that we didn’t even know it’s there already. It’s been there for a while. As in 2020 minus “three years of stealth operations”. If you read carefully below, it will all make much more sense.

George M. Church biography as per Harvard website

Professor at Harvard & MIT, co-author of 580 papers, 143 patent publications & the book “Regenesis”; developed methods used for the first genome sequence (1994) & million-fold cost reductions since (via fluor-NGS & nanopores), plus barcoding, DNA assembly from chips, genome editing, writing & recoding; co-initiated BRAIN Initiative (2011) & Genome Projects (GP-Read-1984, GP-Write-2016, PGP-2005:world’s open-access personal precision medicine datasets); machine learning for protein engineering, tissue reprogramming, organoids, xeno-transplantation, in situ 3D DNA, RNA, protein imaging.

SEE MORE

George Church is Professor of Genetics at Harvard Medical School and Director of  PersonalGenomes.org, which provides the world’s only open-access information on human Genomic, Environmental & Trait data (GET). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in  1994 . His innovations have contributed to nearly all “next generation” DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab’s work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDxAlacrisAbVitro/JunoGenosVeritas Genetics ) & synthetic biology / therapeutics ( JouleGen9EditasEgenesisenEvolvWarpDrive ). He has also pioneered new privacybiosafetyELSIenvironmental & biosecurity policies. He is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has coauthored 537 papers156 patent publications & one book (Regenesis).

THIS IS BGI
THIS IS ILLUMINA

PhD students from (* = main training programs for our group):
Harvard University: Biophysics* , BBS* , MCB , ChemBio* , SystemsBio* , Virology
MIT: HST*ChemistryEE/CSPhysicsMath.
Boston Universty: BioinformaticsBiomedical Engineering
Cambridge University, UK: Genetics

PublicationsCVs-resumesLab members , Co-author netELSI
Technology transfer & Commercial Scientific Advisory Roles
Personal info — News — Awards — Grant proposals
Director of Research Centers: DOE-Biotechnologies (1987), NIH-CEGS (2004), PGP (2005), Lipper Center for Computational Genetics (1998), Wyss Inst. Synthetic Biology (2009). Other centers: Regenesis Inst. (2017), SIAT Genome Engineering (2019), Space Genetics (2016), WICGR, Broad Inst. (1990), MIT Media Lab (2014)

Updated: 15-Jan-02021

The BRAIN initiative[edit]

He was part of a team of six[80] who, in a 2012 scientific commentary, proposed a Brain Activity Map, later named BRAIN Initiative (Brain Research through Advancing Innovative Neurotechnologies).[81] They outlined specific experimental techniques that might be used to achieve what they termed a “functional connectome“, as well as new technologies that will have to be developed in the course of the project,[80] including wireless, minimally invasive methods to detect and manipulate neuronal activity, either utilizing microelectronics or synthetic biology. In one such proposed method, enzymatically produced DNA would serve as a “ticker tape record” of neuronal activity.Wikipedia

SEE THE NAZI ORIGINS OF WYSS HERE

Wyss Institute Will Lead IARPA-Funded Brain Mapping Consortium

January 26, 2016

(BOSTON) — The Wyss Institute for Biologically Inspired Engineering at Harvard University today announced a cross-institutional consortium to map the brain’s neural circuits with unprecedented fidelity. The consortium is made possible by a $21 million contract from the Intelligence Advanced Research Projects Activity (IARPA) and aims to discover the brain’s learning rules and synaptic ‘circuit design’, further helping to advance neurally-derived machine learning algorithms.

The consortium will leverage the Wyss Institute’s FISSEQ (fluorescent in-situ sequencing) method to push forward neuronal connectomics, the science of identifying the neuronal cells that work together to bring about specific brain functions. FISSEQ was developed in 2014 by the Wyss Core Faculty member George Church and colleagues and, unlike traditional sequencing technologies, it provides a method to pinpoint the precise locations of specific RNA molecules in intact tissue. The consortium will harness this FISSEQ capability to accurately trace the complete set of neuronal cells and their connecting processes in intact brain tissue over long distances, which is currently difficult to do with other methods.

Awarded a competitive IARPA MICrONS contract, the consortium will further the overall goals of President Obama’s BRAIN initiative, which aims to improve the understanding of the human mind and uncover new ways to treat neuropathological disorders like Alzheimer’s disease, schizophrenia, autism and epilepsy. The consortium’s work will fundamentally innovate the technological framework used to decipher the principal circuits neurons use to communicate and fulfill specific brain functions. The learnings can be applied to enhance artificial intelligence in different areas of machine learning such as fraud detection, pattern and image recognition, and self-driving car decision making.

See how the Wyss-developed FISSEQ technology is able to capture the location of individual RNA molecules within cells, which will allow the reconstruction of neuronal networks in the 3-dimensional space of intact brain tissue. Credit: Wyss Institute at Harvard University

“Historically, the mapping of neuronal paths and circuits in the brain has required brain tissue to be sectioned and visualized by electron microscopy. Complete neurons and circuits are then reconstructed by aligning the individual electron microsope images, this process is costly and inaccurate due to use of only one color (grey),” said Church, who is the Principal Investigator for the IARPA MICrONs consortium. “We are taking an entirely new approach to neuronal connectomics_immensely colorful barcodes_that should overcome this obstacle; and by integrating molecular and physiological information we are looking to render a high-definition map of neuronal circuits dedicated first to specific sensations, and in the future to behaviors and cognitive tasks.”

Church is Professor of Genetics at Harvard Medical School, and Professor of Health Sciences and Technology at Harvard and MIT.

To map neural connections, the consortium will genetically engineer mice so that each neuron is barcoded throughout its entire structure with a unique RNA sequence, a technique called BOINC (Barcoding of Individual Neuronal Connections) developed by Anthony Zador at Cold Spring Harbor Laboratory. Thus a complete map representing the precise location, shape and connections of all neurons can be generated.

The key to visualizing this complex map will be FISSEQ, which is able to sequence the total complement of barcodes and pinpoint their exact locations using a super-resolution microscope. Importantly, since FISSEQ analysis can be applied to intact brain tissue, the error-prone brain-sectioning procedure that is part of common mapping studies can be avoided and long neuronal processes can be more accurately traced in larger numbers and at a faster pace.

In addition, the scientists will provide the barcoded mice with a sensory stimulus, such as a flash of light, to highlight and glean the circuits corresponding to that stimulus within the much more complex neuronal map. An improved understanding of how neuronal circuits are composed and how they function over longer distances will ultimately allow the team to build new models for machine learning.

The multi-disciplinary consortium spans 6 institutions. In addition to Church, the Wyss Institute’s effort will be led by Samuel Inverso, Ph.D., who is a Staff Software Engineer and Co-investigator of the project. Complementing the Wyss team, are co-Principal Investigators Anthony Zador, Ph.D., Alexei Koulakov, Ph.D., and Jay Lee, Ph.D., at Cold Spring Harbor Laboratory. Adam Marblestone, Ph.D., and Liam Paninski, Ph.D. are co-Investigator at MIT and co-Principal Investigator at Columbia University, respectively. The Harvard-led consortium is partnering with another MICrONS team led by Tai Sing Lee, Ph.D. of Carnegie Mellon University as Principal investigator under a separate multi-million contract, with Sandra Kuhlman, Ph.D. of Carnegie Mellon University and Alan Yuille, Ph.D. of Johns Hopkins University as co-Principal investigators, to develop computational models of the neural circuits and a new generation of machine learning algorithms by studying the behaviors of a large population of neurons in behaving animals, as well as the circuitry of the these neurons revealed by the innovative methods developed by the consortium.

“It is very exciting to see how technology developed at the Wyss Institute is now becoming instrumental in showing how specific brain functions are wired into the neuronal architecture. The methodology implemented by this research can change the trajectory of brain mapping world wide,” said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. – WYSS Institute

IARPA is CIA’s DARPA.
DARPA IS RAN BY PENTAGON AND IARPA BY CIA.
IARPA IS EVEN MORE SECRETIVE, DARING AND SOCIOPATHIC.

Machine Intelligence from Cortical Networks (MICrONS)

Intelligence Advanced Research Projects Activity (IARPA)

Brain Research through Advancing Innovative Neurotechnologies. (BRAIN)

Background
The science behind Obama’s BRAIN project. (BrainFacts, 15Apr-2013 | Jean-François Gariépy)
Wyss Institute Will Lead IARPA-Funded Brain Mapping Consortium (Wyss, 26-Jan-2016 |)
Project Aims to Reverse-engineer Brain Algorithms, Make Computers Learn Like Humans (Scientific Computing, 4-Feb-2016 | Byron Spice)
The U.S. Government Launches a $100-Million “Apollo Project of the Brain” (Scientific American, 8-Mar-2016 | Jordana Cepelewicz)

Grant Proposal
Tasks 2 & 3 PDF Harvard, Wyss, CSHL, MIT.
Task 1. CMU.


Molecular TickertapeRelated Projects:

Full Rosetta brains in situ
A. Activity (MICrONS = Ca imaging) (Alternative=Tickertape, see figure to right)
B. Behavior (MICrONS & Alt = traditional video)
C. Connectome (MICrONS & Alt = BOINC via Cas9-barcode)
D. Developmental Lineage (via Cas9-barcode)
E. Expression (RNA & Protein via FISSEQ)

Building brain components, circuits and organoids.
Busskamp V, Lewis NE, Guye P, Ng AHM, Shipman S, Byrne SS, Sanjana NE, Li Y, Weiss R, Church GM (2014)
Rapid neurogenesis through transcriptional activation in human stem cells. Molecular Systems Biology MSB 10:760:1-21

SOURCE

Flagship Pioneering’s Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

Tessera Therapeutics emerges from three years of stealth operations to pioneer Gene Writing™ as a new genome engineering technology and category of genetic medicine

(PRNewsfoto/Flagship Pioneering)

NEWS PROVIDED BY Flagship Pioneering 

Jul 07, 2020, 08:00 ET


CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ — Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source.

Tessera’s Gene Writing platform is a potentially revolutionary breakthrough for genetic medicine that addresses key limitations of gene therapy and gene editing. Gene Writing technology can alter the genome by efficiently inserting genes and exons (parts of genes), introducing small insertions and deletions, or changing single or multiple DNA base pairs. The technology could enable cures for diseases that arise from errors in the genome, including monogenic disorders. It could also allow precise gene regulation in other diseases such as neurodegenerative diseases, autoimmune disorders, and metabolic diseases.

“While profound advancements in genetic medicine over the last two decades had therapeutic promise for many previously untreatable diseases, the intrinsic properties of existing gene therapy and editing have significant shortcomings that limit their benefits to patients,” says Noubar Afeyan, Ph.D., founder and CEO of Flagship Pioneering and Chairman of Tessera Therapeutics. “Our scientists have invented a new technology, called Gene Writing, that has the ability to write therapeutic messages into the genomes of somatic cells. We created Tessera to pioneer its applications for medicine. However, the breakthrough is broad and could be applied to many different genomes from humans to plants to microorganisms.”

A New Era of Genetic Medicine

Geoffrey von Maltzahn, Ph.D., an MIT-trained biological engineer; Jacob Rubens, Ph.D., an MIT-trained synthetic biologist; and other scientists at Flagship Labs, the enterprise’s innovation foundry, co-founded Tessera in 2018 to create a platform that could design, make, and launch Gene Writing medicines. A General Partner at Flagship Pioneering, von Maltzahn has co-founded numerous biotechnology companies, including Sana Biotechnology, Indigo Agriculture, Kaleido Biosciences, Seres Therapeutics, and Axcella Health.

“DNA codes for life. But sometimes our DNA is written improperly, driving an enormous variety of diseases,” says von Maltzahn, Tessera’s Chief Executive Officer. “We started Tessera Therapeutics with a simple question: ‘What if Nature evolved a better solution than CRISPR for inserting curative therapeutic messages into the genome?’ It turns out that engineered and synthetic mobile genetic elements offer the potential to go beyond the limitations of gene editing technologies and allow Gene Writing. Our outstanding team of scientists is focused on bringing the vast promise of this new technology category to patients.”

Mobile genetic elements, the inspiration for Gene Writing, are evolution’s greatest genomic architect. The first mobile genetic element was discovered by Barbara McClintock, who won the 1983 Nobel Prize for revealing the mobile nature of genes. Mobile genetic elements code for the machinery to move or copy themselves into a new location in the genome, and they have been selected over billions of years to autonomously and efficiently “write” their DNA into new genomic sites. Today, mobile genetic elements are among the most abundant and ubiquitous genes in nature.

Over the past two years, Tessera has been mining genomes to discover novel mobile genetic elements and engineering them to create Gene Writing technology.

Tessera’s Gene Writers write therapeutic messages into the genome using RNA or DNA templates. RNA-based Gene Writing uses an RNA template and Gene Writer protein to either write a new gene into the genome or guide the rewriting of a pre-existing genomic sequence to make a small substitution, insertion, or deletion. DNA-based Gene Writing uses a DNA template to write a new gene into the genome.

By harnessing the biology of mobile genetic elements, Gene Writing holds the potential to overcome the limitations of current genetic medicine approaches by:

  • Efficiently writing small and large alterations to the genome of somatic cells with minimal reliance upon host DNA repair pathways, unlike nuclease-based gene editing technologies.
  • Permanently adding new DNA to dividing cells, unlike AAV-based gene therapy technologies.
  • Writing new DNA sequences into the genome by delivering only RNA.
  • Allowing repeated administration of treatments to patients in order to dose genetic medicines to effect, which is not possible with current gene therapies.

Tessera has licensed Flagship Pioneering’s intellectual property estate, which was begun in 2018 with seminal patent filings supporting both RNA and DNA Gene Writing technologies.

Tessera’s Scientific Advisory Board includes Luigi Naldini, David Schaffer, Andrew Scharenberg, Nancy Craig, George Church, Jonathan Weissman, and John Moran, who collectively have decades of experience in developing gene therapies and gene editing technologies, and also have commercial expertise from 4D, UniQure, Casebia, Cellectis, Magenta, and Editas. Tessera’s Board of Directors includes John Mendlein, Flagship Executive Partner and former CEO of multiple companies; Melissa Moore, Chair of Tessera’s Scientific Advisory Board, Chief Scientific Officer of Moderna, member of the National Academy of Sciences, and founding co-director of the RNA Therapeutics Institute; Geoffrey von Maltzahn; and Noubar Afeyan. The 30-person R&D team at Tessera has deep genetic medicine and startup expertise, including alumni from Editas, Intellia, Beam, Casebia, and Moderna.

About Tessera Therapeutics
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing™, a new biotechnology designed to offer scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing, while eliminating important limitations in their reach, utilization and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-class category companies to transform human health and sustainability.

About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $34 billion in aggregate value. To date, Flagship is backed by more than $4.4 billion of aggregate capital commitments, of which over $1.9 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics, Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS). – Flagship Pioneering

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

I have more memes confirmed than WHO has Covid cases

Pfizer sees Covid-19 as ‘durable’ revenue stream as profits rise

Pfizer CEO Albert Bourla at the Pfizer-BioNtech Covid-19 vaccine factory in Belgium, where capacity is ramping up

John BIERS, Tue, May 4, 2021, AFP via Yahoo News

Pfizer sharply increased its 2021 profit projections on Tuesday, citing much higher Covid-19 vaccine sales which are on track to provide a “durable” revenue stream in the wake of the pandemic.

The drugmaker reported a jump in first-quarter profits based on surging revenues, with nearly one-fourth of sales coming from Covid-19 vaccines.

With German partner BioNTech, the pharma giant is ramping up vaccine production and now estimates 2021 revenues of $26 billion from the vaccine, up from the $15 billion projected in February.

But the surging profits have drawn criticism as governments face pressure to step in to ensure vaccines are provided to underserved countries.

Pfizer, which says it is on the cusp of winning US approval for individuals 12 to 15 years old to receive its vaccine, is holding talks with “basically all governments of the world” about providing booster shots through 2024, Chief Executive Albert Bourla told analysts on a conference call Tuesday.

The company is studying the efficacy of giving the jabs six or more months after the second vaccine dose, and developing doses that could be stored at standard refrigerated temperature for up to 10 weeks.

Bourla expects “durable demand” for Covid-19 vaccines, similar to that of the flu vaccine.

“It is our hope that the Pfizer-BioNTech vaccine will continue to have a global impact by helping to get the devastating pandemic under control and helping economies around the world not only open, but stay open,” Bourla said in prepared remarks.

That would create “a scenario in which Pfizer can continue to be both a leader and a beneficiary,” he said.

Pfizer has won wide praise for its technological prowess in developing a game-changing vaccine in record time. However, critics called the profits troubling given the divide in vaccine availability between rich and poor countries.

World Health Organization chief Tedros Adhanom Ghebreyesus last month decried a “shocking imbalance in the global distribution of vaccines” and called for efforts to fortify the WHO’s Covax programs, which aims to ensure that poorer nations can access the shots.

India and South Africa are leading an effort in the World Trade Organization to waive intellectual property and patent rules, at least temporarily, which would open the door to broader production of vaccines at a time when the virus is causing mass misery in India and some other countries.

President Joe Biden said Tuesday he had not made a decision on whether to support a vaccine waiver, but that the United States was moving “as quickly as we can” to export doses.

Biden also said he was ready to “immediately” begin vaccinations for 12 to 15-year-olds as soon as Pfizer’s Covid shot is approved by regulators for the age group.

Pfizer reported net income of $4.9 billion, up 45 percent from the same period of the prior year.

Revenues also jumped 45 percent to $14.6 billion, including $3.5 billion in Covid-19 vaccine sales.

The results include the lift from Covid-19 vaccines, which generated profit margins of “high-20s,” implying around $900 million in profits in the most recent quarter.

As of May 3, Pfizer and BioNTech have shipped about 430 million doses of the vaccine to 91 countries around the world.

The company has reached an agreement to provide up to 40 million doses for Covax, a globally-pooled coronavirus vaccine procurement effort aimed at providing vaccines to low- and middle-income economies.

However, the company on Tuesday pointed to a series of deals to expand offerings in richer countries, including the United States, the European Union, Canada and Israel.

– Criticism of profits –

Pfizer has defended its approach to vaccine pricing, saying it has moderated pricing through a “pandemic phase” that could last into 2022 at levels “to encourage broad access.”

The company said it is charging $19.50 per vaccine dose in the United States, but has not disclosed its US profit margin.

Zain Rizvi, a law and policy researcher at progressive Public Citizen advocacy group, said Pfizer’s rising profits showed the need for governments to take action to save lives.

“Pfizer is cashing in on the crisis and hoarding technology, even as billions of people around the world go without a vaccine,” Rizvi said in an email to AFP.

“Pfizer’s profiteering shows the urgent need for governments to step-in. Governments should require Pfizer to share technology with manufacturers around the world to help ramp up global production.”

The company is building more capacity and expects to manufacture at least three billion doses in 2022, up from 2.5 billion now expected in 2021. In February, Pfizer said it expected to produce up to two billion doses in 2021.

Pfizer shares rose 0.3 percent to $39.95.

Pfizer sees robust COVID-19 vaccine demand for years, $26 bln in 2021 sales

REUTERS

Pfizer Inc (PFE.N) has just raised its forecast for 2021 COVID-19 vaccine sales by more than 70% to $26 billion and said demand from governments around the world fighting to halt the pandemic could contribute to its growth for years to come.

The company said it expects to file for full U.S. approval of the vaccine in May for people over the age of 16, as it is now only authorized for emergency use. It also expects to hear soon from U.S. regulators on expansion of the vaccine’s emergency use authorization (EUA) for children ages 12-15.

Revenue from the vaccine – developed with German partner BioNTech SE – is expected to account for more than one third of Pfizer’s sales this year.

The forecast is based on contracts to deliver 1.6 billion vaccine doses this year. The company expects to sign more deals for this year and is in supply talks with several countries for 2022 and beyond.

“Based on what we’ve seen, we believe that a durable demand for our COVID-19 vaccine – similar to that of the flu vaccines – is a likely outcome,” Chief Executive Albert Bourla said.

The two-shot vaccine was Pfizer’s top-selling product in the first quarter. Expenses and profit from the vaccine are split 50-50 between Pfizer and BioNTech.

Given persistent infections globally and ongoing discussions with governments, Mizuho analyst Vamil Divan said the 2021 forecast could increase further and spill over to future years.

Daily vaccination rates for adults in the United States are off more than 25% since hitting a peak in mid-April. Authorization in children would expand the vaccine-eligible population by millions of people.

Pfizer said it expects to have safety and efficacy data for children ages 2-to-11 in September, when it plans to ask for further expansion of the EUA for that age group.

The company has also filed new data with U.S. regulators that would allow the vaccine to be stored at standard refrigerator temperatures for up to four weeks, up from five days currently.

Pfizer logo seen outside their building in Manhattan, New York City, New York, U.S., March 2, 2021. REUTERS/Carlo Allegri/File Photo
Pfizer logo seen outside their building in Manhattan, New York City, New York, U.S., March 2, 2021. REUTERS/Carlo Allegri/File Photo

Pfizer and BioNTech aim to produce up to 2.5 billion COVID-19 vaccine doses this year, 900 million of which are not yet included in the New York-based drugmaker’s sales forecast.

If Pfizer sells that number of doses at similar prices, the vaccine’s sales in 2021 could be more than 50% above the projected $26 billion.

Moderna Inc (MRNA.O) has forecast $18.4 billion in 2021 sales of its similar COVID-19 vaccine.

Pfizer expects to profit from the vaccine, while some drugmakers including Johnson & Johnson (JNJ.N) have said their vaccine will be sold on a not-for-profit basis until the end of the pandemic.

Pfizer aims to manufacture at least 3 billion doses of the vaccine next year. It also expects to have safety and immunogenicity data from a third booster dose of the vaccine in July.

Pfizer and BioNTech have published data showing impressive durability for their vaccine at least six months after vaccination. Still, Bourla said he believes regular boosters will be needed to maintain high levels of immunity, and governments around the world have started signing deals for the shots.

The COVID-19 vaccine generated $3.5 billion in revenue in the first quarter, exceeding analysts’ estimates of $3.28 billion, according to Refinitiv data.

Total revenue for the quarter of $14.6 billion, topped analysts’ forecasts of $13.5 billion.

It plans to boost R&D spending to fuel drug discovery using the messenger RNA technology in the COVID-19 vaccine. The company is developing two flu vaccines that are expected to enter clinical trials in the third quarter.

Pfizer shares were down slightly in afternoon trading. – REUTERS

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

I have a feeling most of the World will be surprised to find out it was enrolled without informed consent in a vaccine trial

Australian Health Minister Greg Hunt has spilled the beans recently on live TV, for millions to hear, but when the mind is blind, you need to wait until the clip reaches some Romanian researcher stranded in Morocco, or something. Luckily the Internet can make this possible and here we are, maybe more people “click” now.

Normally, I avoid posting this type of sound-bites here without a consistent context, but I think this one deserves an exceptions because it speaks volumes in seconds and doesn’t really require much more context than I’ve already added.

Worth mentioning that, according to the ethical principles of clinical research, trial subjects for experimental medical treatments cannot be blood or organ donors.

BONUS, FOR AMUSEMENT

DEFINITELY NOT THAT LARGE, BY INDIAN SCALES.

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

You’ve likely heard of IG Farben, bud have you ever heard of American IG and the follow up story?

Imagine that the brutal experiments at Auschwitz were better concealed and the prisoners were drugged and brainwashed to believe that’s the best world out there for them. Then find out that the management has never stopped winning, expanding and perfecting their business model, up to today’s Great Reset.

good stuff that i had to leave out the video documentary:

Rockefellers brought the Nazi doctors and researchers to the US

SOURCE

ANSCO

Founded in Binghamton, New York, in 1901, Ansco was a manufacturer of photographic products and film. Ansco was originally founded through the merger of E. Anthony & Company and Scovill Manufacturing. In 1928, Ansco merged with Agfa to form Agfa-Ansco. The new corporation was a division of General Aniline and Film (GAF) Corporation, which was controlled by the German chemical cartel IG Farben. After Germany declared war on the United States in 1941, the United States Government seized the assets of GAF, including Agfa-Ansco. In 1943, the company removed “Agfa” from its name, once again becoming Ansco. The United States Justice Department oversaw Ansco’s operation until 1965, when government-held stock in GAF was sold to the public. In 1977, GAF eliminated its line of consumer photography products, including those manufactured by Ansco at the Binghamton facility. GAF also sold the Ansco trademark to Haking Enterprises. GAF continued to manufacture film at the Binghamton plant for industrial and medical use until 1981, when it sold the plant to Anitec Image Corporation. Over the next two decades, the former Ansco facility was sold several times, and in 2000, it was demolished.

Prior to the late 1970s, dozens of asbestos-containing materials were utilized in the construction and maintenance of buildings at Ansco’s Binghamton facility, including fireproof insulation, pipe covering and insulating cement. Inhaling dust from the application and removal of asbestos-containing materials placed workers at risk for developing an asbestos-related disease, such as mesothelioma or lung cancer.

Fireproof insulation was applied to structural steel during the construction of buildings at Ansco. Fireproofing materials were manufactured as a dry mixture of asbestos, linen and cement, packaged in fifty-pound paper bags. The dry mixture was mixed with water and sprayed onto the structural steel using a hose. Pouring, mixing and spraying fireproof insulation created clouds of asbestos-containing dust. After the fireproofing material was applied, it was typical for tradesmen, such as electricians or pipefitters, to scrape the fireproofing material from structural steel in order to install pipes and conduits. When the fireproof insulation was disturbed, asbestos fibers and dust became airborne.

Workers applied asbestos-containing pipe covering to pipes at the Binghamton Ansco facility. Pipe covering was applied to numerous piping systems in order to maintain stable internal temperatures and to protect pipes from damage. When pipe covering was applied, asbestos fibers were emitted. Insulating cement was also applied to pumps, valves and other equipment. It was manufactured as a powder and mixed with water to prepare it for application. Mixing insulating cement caused asbestos-containing dust to become airborne.

source:

What’s Bayer been up to lately?
We find out from their website:

The Bio Revolution is redefining innovation in the life sciences. How this might be a game changer.

The life sciences have made great advances in the past years. Biology, life sciences and the megatrend of digitization are growing closer together, enabling new inventions that impact our daily lives in a scope that we speak of a Bio Revolution. This revolution is reinforced by rapid increases in computing power and the emergence of new capabilities in AI, automation, and data analytics. These trends are further accelerating the pace of innovation and the potential for higher R&D productivity in the life sciences.

All this has led to new ways to understand and explore biology. The range of life forms on earth is incredibly complex and diverse. However, the methods to analyze them can be remarkably similar. Technologies and methods are transcending disciplinary boundaries even faster.

The implications across the life sciences can be enormous:

For human health, for example, a deeper understanding of the relationship between genetics and disease has led to the emergence of precision medicine, which can potentially be more effective than the one-size-fits-all therapies of the past. In the future, new technologies could help the healthcare industry not only treat, but cure or even prevent diseases. New gene and cell therapies, for example, aim to cure genetic diseases, potentially enabling sustainable organ replacement or reversing autoimmune diseases.

The Bio Revolution has the potential to help address some of the most critical global challenges, from climate change to pandemics, chronic diseases, and worldwide food security. Experts estimate that a significant portion of the economic impact of biological applications will be in health care, agriculture, and consumer products.3 Already today, the Bio Revolution with its convergence of science and technology has created an explosion of research projects in science and business. Each year, the amount of Intellectual Property related to the Bio Revolution is increasing.4 This can be seen, for example, by the number of patents in CrispR or plant biotech. In short: the revolution is gaining momentum and holds a great promise for health and food alike.

Total number of CRISPR patent applications worldwide per year from 1984 to 2018.

Quote symbolFueled by digitalization, growing connectivity, and falling costs, important advances in biotechnology are intertwined with more systemic shift in how bio-innovation is undertaken and who is involved. Microbiome technologies, advanced genomics, gene editing and synthetic biology are among key enabling technologies that have the potential to change the face of bio-innovation. This broader redefinition of bio-innovation creates new prospects to help address important nutrition, environmental and development needs.

World Economic Forum, Bio-Innovation Dialogue Initiative

.At the Forefront of the Bio Revolution

As a leading life science company, Bayer is aligned with the long-term market trends in health and nutrition and offers innovative and sustainable solutions to tackle some of the key challenges for humanity. Bayer brings to the table an extensive knowledge of human and plant science, supported by its expertise in regulatory processes and an impressive global footprint to ultimately bring innovations from labs to market. https://www.youtube-nocookie.com/embed/EYE1gya7XiM?autoplay=1&start=0&rel=0

The Bio Revolution marks the beginning of a new era: Innovations enabled by the convergence of biology and technology have the potential to significantly improve our lives, our nutrition, and our health.

Did you know that Bayer is at the forefront of the wave of innovation coming from the Bio Revolution?

The Bio Revolution is expected to transform healthcare and agriculture over the next decades – but the revolution is already happening now. With its newly established cell and gene therapy platform in Pharmaceuticals and innovative gene-editing tools such as CRISPR, Bayer operates at the core of the Bio Revolution and has tremendous opportunities to improve health and nutrition.

In Pharma, Bayer’s new Cell & Gene Therapy (CGT) platform steers our strategy in the area and orchestrates our activities along the value chain providing an innovation ecosystem for the companies – including BlueRock Therapeutics and Asklepios BioPharmaceutical (AskBio), which are fully owned by Bayer but operate autonomously. These therapies hold the potential to significantly impact patients’ lives by moving from treating symptoms to potentially curative approaches.

Bayer’s development portfolio of cell and gene therapies already comprises eight advanced assets in different stages of clinical development. These are applicable in multiple therapeutic areas with high unmet need, such as neurodegenerative, neuromuscular and cardiovascular indications, with programs in Pompe disease, Parkinson’s disease, hemophilia A, and congestive heart failure. With over 15 preclinical assets in the cell and gene therapy field, the pipeline is expected to grow steadily year by year.

Yet Bayer is not only using biotechnology to advance health – the promise for agriculture is just as inspiring. In the Crop Science Division, for example, tools like CRISPR can make changes to plant DNA with more precision than ever before and make plants more weather- or disease-resistant, enabling farmers to grow more or better-quality products under changing conditions.

Advancing genetic solutions for a sustainable future (1)PreviousNext

Did you know that Leaps by Bayer invests into potentially disruptive technologies to tackle some of the largest, unsolved challenges in the life sciences?

With Leaps by Bayer – our impact investment approach utilizing venture capital – we are constantly scanning for additional potential breakthroughs that hold promise to either cure or treat people from diseases or help feed a growing population with less impact on the environment.

$1 Billion

Since 2015, Leaps by Bayer has invested over $1 billion in ventures that tackle fundamental breakthroughs and shift core paradigms in our industries.

Leaps by Bayer has an investment focus on potentially disruptive solutions in the fields of healthcare and agriculture. The Leaps investment approach is remarkable: It aims to invest into or build up new innovative companies. Bayer supports those companies by enabling the exchange of proprietary assets, which can include sharing own patents or providing access to the Bayer network’s technical capabilities and 150 years of expertise. The companies remain autonomous with respect to decision making, while Leaps facilitates and supports them in a so-called active incubation process. Experienced team members actively engage in the young companies’ development by providing resources and helping them to steer the initial strategic direction. Today, the investment portfolio includes more than 35 companies advancing potential breakthrough technologies.

Quote symbolLeaps is our way of thinking big.

Werner Baumann, CEO of Bayer AG

Many Leaps ventures have made significant progress towards unlocking the potential of new technology platforms with a promising and transformative potential. BlueRock Therapeutics, for example, started as a Leaps investment and is now an integral part of Bayer’s CGT platform and just received clearance to proceed with a phase I trial in Parkinson’s disease.

Other companies, like the biopharmaceutical player Triumvira, are specialized on next generation immuno-oncology treatments. Triumvira focuses on novel T-cell therapies that aim to be safer and more efficacious than current cell therapy cancer treatments. Treating, curing and preventing cancer is one of the focus areas of Leaps by Bayer, since this group of diseases still represents one of today’s biggest health challenges with limited curative or preventative therapies available.

Quote symbolWe face a huge disease burden, and the way we produce food isn’t sustainable for the planet. I believe the Bio Revolution can help us overcome these issues.

Jürgen Eckhardt, Head of Leaps by Bayer

Leaps is also investing in the development of sustainable biotechnological solutions in the field of agriculture. One of the ventures in this field is Joyn Bio, a company that aims to significantly reduce the environmental impact of synthetic nitrogen fertilizers through a technology that fixes nitrogen into the soil. Nitrogen is one of the most important nutrients essential for every plant to grow, however, its use and production as a fertilizer is estimated to contribute 3-5% to all global greenhouse gas emissions. Joyn Bio is working on an engineered microbe that enables cereal crops like corn, wheat, and rice to convert nitrogen from the air into a form they can use to grow. This technology may have the potential to help farmers use nitrogen in new ways, and as a result, reduce agriculture’s environmental footprint.

Leaps portfolio

The Leaps by Bayer investment portfolio includes more than 35 companies.

At least that’s what Bayer says. All I know is that they’re still running the show.

Ex-Standard Oil

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We gave up on our profit shares from masks, if you want to help us, please use the donation button!
We think frequent use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness.
Get it here!